ATE412404T1 - Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon - Google Patents

Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon

Info

Publication number
ATE412404T1
ATE412404T1 AT04735713T AT04735713T ATE412404T1 AT E412404 T1 ATE412404 T1 AT E412404T1 AT 04735713 T AT04735713 T AT 04735713T AT 04735713 T AT04735713 T AT 04735713T AT E412404 T1 ATE412404 T1 AT E412404T1
Authority
AT
Austria
Prior art keywords
buprenorphine
salt
oral pharmaceutical
pharmaceutical compositions
stable oral
Prior art date
Application number
AT04735713T
Other languages
English (en)
Inventor
Francis Vanderbist
Antonio Sereno
Philippe Baudier
Original Assignee
Galephar M F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galephar M F filed Critical Galephar M F
Application granted granted Critical
Publication of ATE412404T1 publication Critical patent/ATE412404T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04735713T 2004-06-02 2004-06-02 Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon ATE412404T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BE2004/000081 WO2005117838A1 (en) 2004-06-02 2004-06-02 Stable oral pharmaceutical compositions of buprenorphine and derivatives

Publications (1)

Publication Number Publication Date
ATE412404T1 true ATE412404T1 (de) 2008-11-15

Family

ID=34957905

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04735713T ATE412404T1 (de) 2004-06-02 2004-06-02 Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon

Country Status (4)

Country Link
EP (1) EP1750675B1 (de)
AT (1) ATE412404T1 (de)
DE (1) DE602004017514D1 (de)
WO (1) WO2005117838A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271788A1 (en) * 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
RS51211B (sr) 2006-04-04 2010-12-31 Emodis Gmbh. Primena formulacija koje sadrže kapa-opioid receptor-agoniste za tretman disocijativnih poremećaja
GB2461681A (en) * 2008-04-17 2010-01-13 Pharmasol Ltd Buprenorphine liquid spray formulation with solvent and antioxidant
US8491937B2 (en) * 2007-02-15 2013-07-23 Wyeth Llc Stability in vitamin and mineral supplements
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
AU2013245546C1 (en) * 2011-09-19 2017-08-24 Orexo Ab New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
MX361757B (es) * 2011-09-19 2018-12-13 Orexo Ab Nueva composicion farmaceutica resistente al abuso para el tratamiento de la dependencia de opioides.
BR112015025684A2 (pt) * 2013-04-08 2017-07-18 Indivior Uk Ltd método para proporcionar um ou mais opióide(s) a um indivíduo, forma de dosagem, método para tratar ou prevenir dor e método para tratar ou prevenir dependência ou vício
RU2635993C1 (ru) * 2016-09-09 2017-11-17 Закрытое акционерное общество "Научно-производственное объединение "ДОМ ФАРМАЦИИ" Композиция убихинола для парентерального введения и способ её получения

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1302682B1 (it) * 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina
GB0214147D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Formulations

Also Published As

Publication number Publication date
EP1750675B1 (de) 2008-10-29
EP1750675A1 (de) 2007-02-14
WO2005117838A1 (en) 2005-12-15
DE602004017514D1 (de) 2008-12-11

Similar Documents

Publication Publication Date Title
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
DK1157037T3 (da) GCSF-konjugater
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
CY1110664T1 (el) Ενδορινικες συνθεσετς
NO20042844L (no) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister
UA94065C2 (en) Dihydropseudoerythromycin derivatives
TR200401793T4 (tr) Perindopril tuzu ve bunu içeren farmasötik bileşimler.
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE528009T1 (de) Reepithelialisierende pharmazeutische zusammensetzungen, die xanthangummi enthalten
MY147373A (en) Piperazine derivatives as antimalarial agents
ATE412404T1 (de) Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
IS8334A (is) Æxilseyðandi samsetningar sem samanstanda af defíbrótíði stöku eða blönduðu með öðrum æxliseyðandi miðlum
SE0300457D0 (sv) Novel compounds
NZ523606A (en) Pharmaceutical compositions and methods for use
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties